US Court upholds AstraZeneca Seroquel XR patent
In some good news for the company, Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last night that the US District Court for the District of New Jersey has found the formulation patent protecting its blockbuster antipsychotic drug Seroquel (quetiapine fumarate) extended release tablets to be valid.
The court also ruled that Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals, Torrent Pharma, Mylan Pharmaceuticals and Mylan Inc have infringed the Seroquel XR formulation, the patent on which expires in 2017.
This follows a decision made in the UK on March 22, 2012, which found the formulation patent protecting Seroquel XR to be invalid. In the Netherlands, however, on March 7, the District Court in The Hague found the formulation patent protecting Seroquel XR to be valid, AstraZeneca noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze